Treatment as prevention wong


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • These data show that in serodiscordant couples in monogamous relationships, the HIV+ partner if on ARVs has a much lower risk of transmitting HIV to his or her partner than those who are not on ARVs. Extrapolated, tells us if we find HIV infected persons earlier as they have in DC, SF and BC, and effectively get them on effective HIV meds, we can decrease transmission rates in a very measurable manner.
  • These are data from San Francisco DPH demonstrating what’s being referred to as “community viral load” in log copies/mL on the X axis and new HIV diagnoses on the Z axis. Unfrotunately, no denominator data. Period was from 2004 to 2008. SF was a demonstration site in 2004-5 for verbal consent, and in 2006, went to opt-out testing. The take homes here are: 1) verbal consent was effective; 2) the community viral loads early in the demonstration were high– around 100,000 copies/mL at time of diagnosis– by 2008, the viral loads were around 15,000 copies/mL. The biologic impact of this is lower transmission rates (transmission is directly tied to types of risk behaviors and viral load). I can’t say more about this– the SF DPH is very careful to say the data are not robust enough to say they’re affecting HIV incidence yet, though the trend would suggest this.
  • These are data from British Columbia, Canada (includes Vancouver– very high HIV rates). The Canadians use an opt-out, verbal discussion testing format that started I believe in the mid 2000s. They’re finding trends similar to the SF DPH– community viral load down, getting more and more people on ARVs earlier, and the public health impact has been a persistently falling new case rate– in spite of continued high-risk behavior as indicated by the other STD rates (increasing syphilis, GC and chlamydia rates– generally used as surrogates for unprotected sex exposures).
  • Treatment as prevention wong

    1. 1. Treatment as Prevention Michael Wong, MDBeth Israel Deaconess Medical Center Harvard Medical SchoolMassachusetts Department of Public Health
    2. 2. Accumulating Data that ART Reduces HIV transmission• Sullivan et al, CROI 2009 – Evaluated the effect of ART on HIV transmission rates in 2993 serodiscordant, monogamous heterosexual couples – ART was prescribed to the HIV+ partner only if clinically indicated by contemporaneous HHS guidelines – Seronegative partner at time of study entry underwent q 3 month HIV testing • Risk for HIV seroconversion: – Partner not on ART: 171 linked events, 3.4/100 CY – Partner on ART: 4 linked events, 0.7/100 CY – This difference is statistically significant
    3. 3. HIV Transmission Risk in Heterosexual Serodiscordant Couples Initiating ARV  92% lower HIV transmission risk in African serodiscordant couples with HIV-infected partner receiving ARV therapy vs couples with infected partner not receiving ARVs • 102 of 103 cases of confirmed HIV transmission occurred in couples with HIV-infected partner not receiving ARV therapy – ARV use in seropositive partner, adjusted for visit and CD4+ cell count at initiation: • Unadjusted relative risk: 0.17 (95% CI: 0.004-0.94; P = .037) • Adjusted relative risk: 0.08 (95% CI: 0.002-0.57; P = .004)Donnell D, et al. CROI 2010. Abstract 136.
    4. 4. Community Viral Load Mirrors Reduced Rate of New HIV Cases in San Francisco • Retrospective analysis of relationship between community viral load (mean of summed individual HIV-1 RNA results per yr) and new HIV diagnoses 30,000 P = .005 for Mean CVL Mean Community Viral Load association* 1200 25,000 Newly diagnosed and Diagnosed HIV Cases reported HIV cases 1000 Number of Newly (copies/mL) 20,000 800 15,000 798 600 642 10,000 523 518 400 434 5000 200 0 0 2004 2005 2006 2007 2008 Yr*Data insufficient to prove significant association with reduced HIV incidence.Das-Douglas M, et al. CROI 2010. Abstract 33.
    5. 5. Reduction in New HIV Diagnoses in BC: Testing, HAART, and Community VL • Period of declining new HIV diagnoses in BC coincident with increased HIV testing rates, increased uptake of antiretroviral therapy, and decrease in community viral load (1996-2008) – Decline in new HIV diagnoses despite increases in syphilis, gonorrhea, 12,000 chlamydia 1400 HIV-1 RNA, New HIV+ Diagnoses (n) 10,000 Censored at the time of death or move 1200 copies/mL 8000 1000 < 500Patients (n) New HIV+ 500-3499 6000 diagnoses (all) 800 3500-9999 600 4000 10,000-49,999 400 ≥ 50,000 2000 200 0 0 6 7 8 9 0 1 2 3 4 5 6 7 8 9 1 99 199 199 199 200 200 200 200 200 200 200 200 200 200Montaner J, et al. CROI 2010. Abstract 88LB..
    6. 6. Considerations whendiscussing ARVs with a newly diagnosed patient
    7. 7. • What we say to patients: I have some news for you; your HIV test is positive. Now that doesn’t mean you have AIDS, but we should…• What patients hear: Blah, blah, blah, HIV, blah, blah, blah, AIDS…
    8. 8. Why does ART fail?• Adherence• Baseline resistance• Prior ART not disclosed or not recorded• Drug levels and drug-drug interactions• Tissue reservoir penetration• Provider inexperience• Other unknown or yet to be identified causes
    9. 9. Adherence Considerations• Patient lifestyle (shift work, full time new parent, travel, existing responsibilities)• Concurrent medical history (drug-drug interactions; DM; dual or triple diagnosis)• Patient acceptance (“I feel fine; why should I take medications?” “I heard these medications can make you …..”)• Patient life chaos (Is the patient’s medical care their top priority, or are they worried about housing, heating, food, running water?)• Can the patient take medications reliably?
    10. 10. Dual and Triple diagnoses• Dual diagnosis: active mental health disorder and substance abuse (injection, prescription, nonprescription)• Triple diagnosis: includes dual diagnosis and HIV diagnosis.The impact of dual or triple diagnosis cannot be overemphasized in this population.
    11. 11. Other medical considerations• Concurrent active/chronic HBV infection• Undiagnosed HCV infection• Undiagnosed or untreated STD including syphilis• Undiagnosed/untreated LTBI; active MTB infection• HTN, DM, CAD, tobacco/ETOH use,
    12. 12. Pt Gender Age Presenting Conditions Outcome Time to Dx1 M 34 KS, PCP, CMV and diffuse Died 4 months large B cell lymphoma (DLBCL)2 M 45 KS, PCP, multicentric Doing well, KS 8 months Castleman’s Dz, DLBCL and lymphoma in remission3 M 30 PCP, CMV, CNS Died 6 weeks Lymphoma4 M 32 PCP, CMV, KS Doing well; KS 6 months in remission5 M 65 PCP, MAI Doing well 3 months6 M 51 PCP, Burkitt’s Lymphoma Doing well, 6 months Burkitts in remission7 M 48 PCP, Hodgkins Doing well, 3 months Hodgkins in remission8 M 49 KS, Hodgkins Starting chemo 9 months
    13. 13. Always work with your patient where they are and remember this is dynamic.For many patients, HIV therapy is up here, not a basic need.To Providers,HIV therapy is here Maslow’s Hierarchy of Needs
    14. 14. Conventional wisdom is that adherence must be 95% to reduce risk of mutation This means:• If you are on a bid regimen and you miss 1 dose out of 14 your adherence is 93%• If you are on a bid regimen and you miss 2 doses out of 14, your adherence is 86%• If you are on a qd regimen and you miss 1 dose out of 7 your adherence is 86%
    15. 15. Correlation between Adherence and Virologic Failure
    16. 16. FDA Approved ARV Agents, 2010
    17. 17. Simplification of therapy,evolution from 1996-2006
    18. 18. Declining rates of virologic failure of first regimens
    19. 19. Transmission of Resistant Virus: 2006, pooled data from 8 US city assessment, and Vancouver• 0-14% of new infections are ZDV resistant• 0-10% of new infections have PI resistance mutations• 2-14% of new infections have a significant NNRTI mutation• Reports of transmission of HIV resistance to all ARVs exist
    20. 20. Conclusion• HIV Treatment is an effective prevention and public health strategy – Requires infrastructure and funding to sustain medications for existing and newly diagnosed HIV+ patients especially with universalized testing
    21. 21. Conclusion• Treatment is not merely writing a prescription for 1 of 4 first line regimens. Must consider: – Baseline resistance genotype with reliable interpretation* – Assess the patient for support, life chaos, life style, and readiness to take HAART • I always hope to get them to be an HIV expert before we start ARVs. – Assess the patient for concurrent medical and mental health conditions, and carefully assess for drug-drug interactions
    22. 22. Conclusion• Have an established team working with you: – Mental health expert – Social worker/case manager – HIV expert who can help comanage the patient with you and assist with other medical conditions